Blue Trust Inc. Purchases 12,154 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Blue Trust Inc. boosted its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 1,246.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,129 shares of the company’s stock after buying an additional 12,154 shares during the period. Blue Trust Inc.’s holdings in Sana Biotechnology were worth $55,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Baillie Gifford & Co. increased its position in shares of Sana Biotechnology by 5.0% during the 1st quarter. Baillie Gifford & Co. now owns 10,656,279 shares of the company’s stock valued at $106,563,000 after purchasing an additional 506,262 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Sana Biotechnology during the first quarter valued at approximately $1,343,000. ProShare Advisors LLC raised its stake in shares of Sana Biotechnology by 14.8% during the first quarter. ProShare Advisors LLC now owns 32,690 shares of the company’s stock worth $327,000 after acquiring an additional 4,210 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Sana Biotechnology by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 12,155,173 shares of the company’s stock worth $121,552,000 after acquiring an additional 2,358,089 shares during the last quarter. Finally, Capital World Investors boosted its stake in shares of Sana Biotechnology by 255.8% in the 1st quarter. Capital World Investors now owns 5,449,035 shares of the company’s stock valued at $54,490,000 after purchasing an additional 3,917,728 shares in the last quarter. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

Sana Biotechnology Trading Down 4.4 %

SANA opened at $3.50 on Friday. Sana Biotechnology, Inc. has a 1-year low of $2.84 and a 1-year high of $12.00. The firm’s 50 day simple moving average is $4.51 and its two-hundred day simple moving average is $6.00. The company has a market capitalization of $778.63 million, a PE ratio of -3.04 and a beta of 1.42.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). Equities analysts forecast that Sana Biotechnology, Inc. will post -1.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SANA has been the topic of a number of recent research reports. Citigroup raised their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, August 9th. HC Wainwright reduced their price target on Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, August 9th.

Insider Transactions at Sana Biotechnology

In related news, Director Richard Mulligan sold 150,000 shares of Sana Biotechnology stock in a transaction dated Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the completion of the transaction, the director now directly owns 2,848,121 shares of the company’s stock, valued at approximately $11,620,333.68. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 31.10% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.